{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:26:45Z","timestamp":1783013205818,"version":"3.54.6"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Dokuz Eyl\u00fcl University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ovarian cancer (OC) accounts for a significant percentage of cancer-related deaths in women worldwide. A small proportion of ovarian cancers, usually in women under 40, originate from germ cells and stromal cells within the ovary, but the vast majority are epithelial malignancies. The preferred treatment for ovarian malignancies consists of platinum-based chemotherapy and surgical intervention.<\/jats:p>\n                  <jats:p>Chemoresistance in ovarian cancer is a complex problem that significantly impedes tratment efficacy. Many pathways contribute to this resistance, including genetic factors, tumor microenvironment interactions, and lifestyle variables such as obesity. Understanding these mechanisms is crucial for developing effective treatment solutions. The circadian rhythm, or circadian clock, regulates the sleep\u2013wake cycle, body temperature, hormone secretion, metabolism, and many physiological processes. Circadian genes are highly expressed in the ovaries, which regulate ovulation. Disruption of circadian rhythm asociated with many risk factors for ovarian cancer. This article examines the relationship between circadian rhythm and chemotherapy resistance in ovarian cancer, and reviews circadian rhythm to reduce chemotherapy resistance in this context.<\/jats:p>","DOI":"10.1007\/s43032-026-02093-9","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:03:59Z","timestamp":1777907039000},"page":"1079-1090","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chemoresistance in Ovarian Cancer and Association with Circadian Rhythm"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2520-0743","authenticated-orcid":false,"given":"Fatma Seher","family":"Pektopal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7068-5979","authenticated-orcid":false,"given":"Selen","family":"Kum \u00d6z\u015fengezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1558-4534","authenticated-orcid":false,"given":"Zekiye Sultan","family":"Altun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"9","key":"2093_CR1","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.3390\/CANCERS14092230\/S1","volume":"14","author":"J Huang","year":"2022","unstructured":"Huang J, et al. Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study. Cancers (Basel). 2022;14(9):2230. https:\/\/doi.org\/10.3390\/CANCERS14092230\/S1.","journal-title":"Cancers (Basel)"},{"key":"2093_CR2","unstructured":"International Agency for Research on Cancer (IARC). International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. World Health Organization. Available: https:\/\/www.iarc.who.int\/reference\/international-patterns-and-trends-in-ovarian-cancer-incidence-overall-and-by-histologic-subtype\/. Accessed Sep. 24, 2024."},{"issue":"5","key":"2093_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21(5):389\u2013400. https:\/\/doi.org\/10.1038\/s41571-024-00881-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"2093_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/IJWH.S197604","volume":"11","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287\u201399. https:\/\/doi.org\/10.2147\/IJWH.S197604.","journal-title":"Int J Womens Health"},{"issue":"8","key":"2093_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/J.HUMPATH.2005.06.006","volume":"36","author":"J Prat","year":"2005","unstructured":"Prat J, Rib\u00e9 A, Gallardo A. Hereditary ovarian cancer. Hum Pathol. 2005;36(8):861\u201370. https:\/\/doi.org\/10.1016\/J.HUMPATH.2005.06.006.","journal-title":"Hum Pathol"},{"key":"2093_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/341723","author":"A Toss","year":"2015","unstructured":"Toss A, et al. Hereditary ovarian cancer: not only BRCA 1 and 2 Genes. Biomed Res Int. 2015. https:\/\/doi.org\/10.1155\/2015\/341723.","journal-title":"Biomed Res Int"},{"issue":"1","key":"2093_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.30654\/MJGO.10022","volume":"7","author":"S Franji\u0107","year":"2023","unstructured":"Franji\u0107 S. Ovarian cancer is the deadliest of all gynecological tumors. Mathews J Gynecol Obstetr. 2023;7(1):1\u20136. https:\/\/doi.org\/10.30654\/MJGO.10022.","journal-title":"Mathews J Gynecol Obstetr"},{"key":"2093_CR8","doi-asserted-by":"publisher","first-page":"114205","DOI":"10.1016\/J.EJMECH.2022.114205","volume":"232","author":"M Song","year":"2022","unstructured":"Song M, Cui M, Liu K. Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. Eur J Med Chem. 2022;232:114205. https:\/\/doi.org\/10.1016\/J.EJMECH.2022.114205.","journal-title":"Eur J Med Chem"},{"key":"2093_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246246","author":"KL Alatise","year":"2022","unstructured":"Alatise KL, Gardner S, Alexander-Bryant A. Mechanisms of drug resistance in ovarian cancer and associated gene targets. Cancers. 2022. https:\/\/doi.org\/10.3390\/cancers14246246.","journal-title":"Cancers"},{"issue":"4","key":"2093_CR10","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.3892\/ol.2019.10745","volume":"18","author":"B Gao","year":"2019","unstructured":"Gao B, et al. Multidrug resistance affects the prognosis of primary epithelial ovarian cancer. Oncol Lett. 2019;18(4):4262\u20139. https:\/\/doi.org\/10.3892\/ol.2019.10745.","journal-title":"Oncol Lett"},{"issue":"4","key":"2093_CR11","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1208\/S12248-015-9757-1","volume":"17","author":"YK Zhang","year":"2015","unstructured":"Zhang YK, Wang YJ, Gupta P, Chen ZS. Multidrug resistance proteins (MRPs) and cancer therapy. AAPS J. 2015;17(4):802. https:\/\/doi.org\/10.1208\/S12248-015-9757-1.","journal-title":"AAPS J"},{"issue":"36","key":"2093_CR12","doi-asserted-by":"publisher","first-page":"49447","DOI":"10.1007\/S11356-021-15759-5\/FIGURES\/3","volume":"28","author":"A Elfadadny","year":"2021","unstructured":"Elfadadny A, et al. Role of multidrug resistance-associated proteins in cancer therapeutics: past, present, and future perspectives. Environ Sci Pollut Res. 2021;28(36):49447\u201366. https:\/\/doi.org\/10.1007\/S11356-021-15759-5\/FIGURES\/3.","journal-title":"Environ Sci Pollut Res"},{"key":"2093_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS9051299","author":"M Nowak","year":"2020","unstructured":"Nowak M, Klink M. The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer. Cells. 2020. https:\/\/doi.org\/10.3390\/CELLS9051299.","journal-title":"Cells"},{"key":"2093_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2019.00421","author":"H Cheng","year":"2019","unstructured":"Cheng H, Wang Z, Fu L, Xu T. Macrophage polarization in the development and progression of ovarian cancers: an overview. Front Oncol. 2019. https:\/\/doi.org\/10.3389\/FONC.2019.00421.","journal-title":"Front Oncol"},{"key":"2093_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2022.863541","author":"Y Wang","year":"2022","unstructured":"Wang Y, Huang Z, Li B, Liu L, Huang C. The emerging roles and therapeutic implications of epigenetic modifications in ovarian cancer. Front Endocrinol (Lausanne). 2022. https:\/\/doi.org\/10.3389\/FENDO.2022.863541.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2093_CR16","doi-asserted-by":"publisher","first-page":"8760","DOI":"10.1002\/JCP.27535","volume":"234","author":"NK Sun","year":"2019","unstructured":"Sun NK, Kohli A, Huang SL, Chang TC, Chao CCK. Androgen receptor transcriptional activity and chromatin modifications on the ABCB1\/MDR gene are critical for taxol resistance in ovarian cancer cells. J Cell Physiol. 2019;234(6):8760\u201375. https:\/\/doi.org\/10.1002\/JCP.27535.","journal-title":"J Cell Physiol"},{"key":"2093_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBAMCR.2020.118647","author":"JM Wang","year":"2020","unstructured":"Wang JM, et al. ISG15 suppresses translation of ABCC2 via ISGylation of hnRNPA2B1 and enhances drug sensitivity in cisplatin resistant ovarian cancer cells. Biochimica et Biophysica Acta (BBA) - Mol Cell Res\\. 2020. https:\/\/doi.org\/10.1016\/J.BBAMCR.2020.118647.","journal-title":"Biochimica et Biophysica Acta (BBA) - Mol Cell Res\\"},{"issue":"9","key":"2093_CR18","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/SJ.BJC.6604334","volume":"98","author":"AM Calcagno","year":"2008","unstructured":"Calcagno AM, et al. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. Br J Cancer. 2008;98(9):1515\u201324. https:\/\/doi.org\/10.1038\/SJ.BJC.6604334.","journal-title":"Br J Cancer"},{"issue":"7","key":"2093_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/S41568-018-0005-8","volume":"18","author":"RW Robey","year":"2018","unstructured":"Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18(7):452\u201364. https:\/\/doi.org\/10.1038\/S41568-018-0005-8.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2093_CR20","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/J.CRITREVONC.2015.05.012","volume":"96","author":"MP Ween","year":"2015","unstructured":"Ween MP, Armstrong MA, Oehler MK, Ricciardelli C. The role of ABC transporters in ovarian cancer progression and chemoresistance. Crit Rev Oncol Hematol. 2015;96(2):220\u201356. https:\/\/doi.org\/10.1016\/J.CRITREVONC.2015.05.012.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2093_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.DRUP.2016.03.001","volume":"26","author":"JI Fletcher","year":"2016","unstructured":"Fletcher JI, Williams RT, Henderson MJ, Norris MD, Haber M. ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist Updat. 2016;26:1\u20139. https:\/\/doi.org\/10.1016\/J.DRUP.2016.03.001.","journal-title":"Drug Resist Updat"},{"issue":"2","key":"2093_CR22","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3892\/OR.2012.1823","volume":"28","author":"L Yang","year":"2012","unstructured":"Yang L, Li N, Wang H, Jia X, Wang X, Luo J. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1\/P-glycoprotein-mediated drug resistance. Oncol Rep. 2012;28(2):592\u2013600. https:\/\/doi.org\/10.3892\/OR.2012.1823.","journal-title":"Oncol Rep"},{"issue":"2","key":"2093_CR23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.20517\/CDR.2020.107","volume":"4","author":"W Wang","year":"2021","unstructured":"Wang W, Lokman NA, Noye TM, Macpherson AM, Oehler MK, Ricciardelli C. ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome. Cancer Drug Resist. 2021;4(2):485\u2013502. https:\/\/doi.org\/10.20517\/CDR.2020.107.","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"2093_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41598-023-44548-Y","volume":"13","author":"A Marjamaa","year":"2023","unstructured":"Marjamaa A, Gibbs B, Kotrba C, Masamha CP. The role and impact of alternative polyadenylation and miRNA regulation on the expression of the multidrug resistance-associated protein 1 (MRP-1\/ABCC1) in epithelial ovarian cancer. Sci Rep. 2023;13(1):1\u201311. https:\/\/doi.org\/10.1038\/S41598-023-44548-Y.","journal-title":"Sci Rep"},{"issue":"6","key":"2093_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/IJO.2024.5650","volume":"64","author":"M Fu","year":"2024","unstructured":"Fu M, et al. Current data and future perspectives on DNA methylation in ovarian cancer (Review). Int J Oncol. 2024;64(6):1\u201319. https:\/\/doi.org\/10.3892\/IJO.2024.5650.","journal-title":"Int J Oncol"},{"issue":"1","key":"2093_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41392-025-02266-Z","volume":"10","author":"J Song","year":"2025","unstructured":"Song J, et al. Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance. Signal Transduct Target Ther. 2025;10(1):1\u201356. https:\/\/doi.org\/10.1038\/S41392-025-02266-Z.","journal-title":"Signal Transduct Target Ther"},{"issue":"23","key":"2093_CR27","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.3390\/CANCERS13235993","volume":"13","author":"BG Matthews","year":"2021","unstructured":"Matthews BG, Bowden NA, Wong-Brown MW. Epigenetic mechanisms and therapeutic targets in chemoresistant high-grade serous ovarian cancer. Cancers. 2021;13(23):5993. https:\/\/doi.org\/10.3390\/CANCERS13235993.","journal-title":"Cancers"},{"key":"2093_CR28","doi-asserted-by":"publisher","first-page":"863541","DOI":"10.3389\/FENDO.2022.863541\/FULL","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Huang Z, Li B, Liu L, Huang C. The emerging roles and therapeutic implications of epigenetic modifications in ovarian cancer. Front Endocrinol (Lausanne). 2022;13:863541. https:\/\/doi.org\/10.3389\/FENDO.2022.863541\/FULL.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2093_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2199-13-27","volume":"13","author":"X Tan","year":"2012","unstructured":"Tan X, Zhang P, Zhou L, Yin B, Pan H, Peng X. Clock-controlled mir-142-3p can target its activator, Bmal1. BMC Mol Biol. 2012;13(1):1\u20139. https:\/\/doi.org\/10.1186\/1471-2199-13-27.","journal-title":"BMC Mol Biol"},{"issue":"3","key":"2093_CR30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/CLOCKSSLEEP2030022","volume":"2","author":"C Kinoshita","year":"2020","unstructured":"Kinoshita C, Okamoto Y, Aoyama K, Nakaki T. MicroRNA: a key player for the interplay of circadian rhythm abnormalities, sleep disorders and neurodegenerative diseases. Clocks Sleep. 2020;2(3):282. https:\/\/doi.org\/10.3390\/CLOCKSSLEEP2030022.","journal-title":"Clocks Sleep"},{"issue":"1","key":"2093_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ygyno.2010.06.004","volume":"119","author":"Z Li","year":"2010","unstructured":"Li Z, et al. MiR-27a modulates MDR1\/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol. 2010;119(1):125\u201330. https:\/\/doi.org\/10.1016\/j.ygyno.2010.06.004.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2093_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13048-015-0207-6\/FIGURES\/5","volume":"8","author":"KX Sun","year":"2015","unstructured":"Sun KX, Jiao JW, Chen S, Liu BL, Zhao Y. MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1. J Ovarian Res. 2015;8(1):1\u20137. https:\/\/doi.org\/10.1186\/S13048-015-0207-6\/FIGURES\/5.","journal-title":"J Ovarian Res"},{"issue":"5","key":"2093_CR33","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1139\/BCB-2018-0031","volume":"96","author":"T Lv","year":"2018","unstructured":"Lv T, et al. miRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1. Biochem Cell Biol. 2018;96(5):663\u201371. https:\/\/doi.org\/10.1139\/BCB-2018-0031.","journal-title":"Biochem Cell Biol"},{"key":"2093_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2021.145644","author":"J Zhu","year":"2021","unstructured":"Zhu J, Zhou Q, Pan M, Zhou C. Multi-omics analysis of the prognosis and therapeutic significance of circadian clock in ovarian cancer. Gene. 2021. https:\/\/doi.org\/10.1016\/j.gene.2021.145644.","journal-title":"Gene"},{"issue":"1","key":"2093_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1757-2215-4-17","volume":"4","author":"S Kumar","year":"2011","unstructured":"Kumar S, Kumar A, Shah PP, Rai SN, Panguluri SK, Kakar SS. MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res. 2011;4(1):17. https:\/\/doi.org\/10.1186\/1757-2215-4-17.","journal-title":"J Ovarian Res"},{"key":"2093_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/S41419-023-06076-5","author":"T Han","year":"2023","unstructured":"Han T, et al. HLF promotes ovarian cancer progression and chemoresistance via regulating Hippo signaling pathway. Cell Death Dis. 2023. https:\/\/doi.org\/10.1038\/S41419-023-06076-5.","journal-title":"Cell Death Dis"},{"issue":"4","key":"2093_CR37","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/ANNONC\/MDW007","volume":"27","author":"M Petrillo","year":"2016","unstructured":"Petrillo M, et al. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies. Ann Oncol. 2016;27(4):625\u201334. https:\/\/doi.org\/10.1093\/ANNONC\/MDW007.","journal-title":"Ann Oncol"},{"issue":"1","key":"2093_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12935-021-02136-Y","volume":"21","author":"W Xie","year":"2021","unstructured":"Xie W, Sun H, Li X, Lin F, Wang Z, Wang X. Ovarian cancer: epigenetics, drug resistance, and progression. Cancer Cell International. 2021;21(1):1\u201316. https:\/\/doi.org\/10.1186\/S12935-021-02136-Y.","journal-title":"Cancer Cell International"},{"issue":"1","key":"2093_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1006\/EXCR.2000.4838","volume":"256","author":"SH Kaufmann","year":"2000","unstructured":"Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000;256(1):42\u20139. https:\/\/doi.org\/10.1006\/EXCR.2000.4838.","journal-title":"Exp Cell Res"},{"issue":"8","key":"2093_CR40","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0959-8049(99)00124-0","volume":"35","author":"Y Mano","year":"1999","unstructured":"Mano Y, et al. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur J Cancer. 1999;35(8):1214\u20139. https:\/\/doi.org\/10.1016\/S0959-8049(99)00124-0.","journal-title":"Eur J Cancer"},{"key":"2093_CR41","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2147\/OTT.S187015","volume":"12","author":"Y Yang","year":"2019","unstructured":"Yang Y, Li S, Sun Y, Zhang D, Zhao Z, Liu L. Reversing platinum resistance in ovarian cancer multicellular spheroids by targeting Bcl-2. Onco Targets Ther. 2019;12:897\u2013906. https:\/\/doi.org\/10.2147\/OTT.S187015.","journal-title":"Onco Targets Ther"},{"issue":"24","key":"2093_CR42","doi-asserted-by":"publisher","first-page":"17163","DOI":"10.1074\/JBC.M114.558288","volume":"289","author":"J Wang","year":"2014","unstructured":"Wang J, Wu GS. Role of autophagy in cisplatin resistance in ovarian cancer cells. J Biol Chem. 2014;289(24):17163. https:\/\/doi.org\/10.1074\/JBC.M114.558288.","journal-title":"J Biol Chem"},{"issue":"3","key":"2093_CR43","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nrg.2016.150","volume":"18","author":"JS Takahashi","year":"2016","unstructured":"Takahashi JS. Transcriptional architecture of the mammalian circadian clock. Nature Rev Genet. 2016;18(3):164\u201379. https:\/\/doi.org\/10.1038\/nrg.2016.150.","journal-title":"Nature Rev Genet"},{"issue":"12","key":"2093_CR44","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/nrc2747","volume":"9","author":"S Sahar","year":"2009","unstructured":"Sahar S, Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. Nature Rev Cancer. 2009;9(12):886\u201396. https:\/\/doi.org\/10.1038\/nrc2747.","journal-title":"Nature Rev Cancer"},{"issue":"1","key":"2093_CR45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/J.CANLET.2013.09.040","volume":"342","author":"FC Kelleher","year":"2014","unstructured":"Kelleher FC, Rao A, Maguire A. Circadian molecular clocks and cancer. Cancer Lett. 2014;342(1):9\u201318. https:\/\/doi.org\/10.1016\/J.CANLET.2013.09.040.","journal-title":"Cancer Lett"},{"issue":"6315","key":"2093_CR46","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1126\/SCIENCE.AAH4965","volume":"354","author":"J Bass","year":"2016","unstructured":"Bass J, Lazar MA. Circadian time signatures of fitness and disease. Science (1979). 2016;354(6315):994\u20139. https:\/\/doi.org\/10.1126\/SCIENCE.AAH4965.","journal-title":"Science (1979)"},{"issue":"4","key":"2093_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1136\/OEMED-2012-101146","volume":"70","author":"P Bhatti","year":"2013","unstructured":"Bhatti P, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA. Nightshift work and risk of ovarian cancer. Occup Environ Med. 2013;70(4):231. https:\/\/doi.org\/10.1136\/OEMED-2012-101146.","journal-title":"Occup Environ Med"},{"key":"2093_CR48","doi-asserted-by":"publisher","unstructured":"Jim HSL, et al. Common genetic variation in circadian rhythm genes and risk of epithelial ovarian Cancer (EOC). J Genet Genome Res 2015;29(2). https:\/\/doi.org\/10.23937\/2378-3648\/1410017.","DOI":"10.23937\/2378-3648\/1410017"},{"key":"2093_CR49","doi-asserted-by":"publisher","first-page":"1208132","DOI":"10.3389\/FMOLB.2023.1208132\/BIBTEX","volume":"10","author":"L Zhao","year":"2023","unstructured":"Zhao L, et al. Integrative analysis of circadian clock with prognostic and immunological biomarker identification in ovarian cancer. Front Mol Biosci. 2023;10:1208132. https:\/\/doi.org\/10.3389\/FMOLB.2023.1208132\/BIBTEX.","journal-title":"Front Mol Biosci"},{"issue":"4","key":"2093_CR50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/cbr.2016.2153","volume":"32","author":"Y Sun","year":"2017","unstructured":"Sun Y, Jin L, Sui YX, Han LL, Liu JH. Circadian gene CLOCK affects drug-resistant gene expression and cell proliferation in ovarian cancer SKOV3\/DDP cell lines through autophagy. Cancer Biother Radiopharm. 2017;32(4):139\u201346. https:\/\/doi.org\/10.1089\/cbr.2016.2153.","journal-title":"Cancer Biother Radiopharm"},{"issue":"6","key":"2093_CR51","doi-asserted-by":"publisher","first-page":"8945","DOI":"10.3892\/ol.2018.8488","volume":"15","author":"H Xu","year":"2018","unstructured":"Xu H, Wang Z, Mo G, Chen H. Association between circadian gene CLOCK and cisplatin resistance in ovarian cancer cells: a preliminary study. Oncol Lett. 2018;15(6):8945\u201350. https:\/\/doi.org\/10.3892\/ol.2018.8488.","journal-title":"Oncol Lett"},{"key":"2093_CR52","doi-asserted-by":"publisher","first-page":"11897","DOI":"10.2147\/CMAR.S278903","volume":"12","author":"Z Wang","year":"2020","unstructured":"Wang Z, Li F, Wei M, Zhang S, Wang T. Circadian clock protein period2 suppresses the pi3k\/akt pathway and promotes cisplatin sensitivity in ovarian cancer. Cancer Manag Res. 2020;12:11897\u2013908. https:\/\/doi.org\/10.2147\/CMAR.S278903.","journal-title":"Cancer Manag Res"},{"key":"2093_CR53","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20202683","author":"Z Wang","year":"2020","unstructured":"Wang Z, et al. The circadian rhythm and core gene Period2 regulate the chemotherapy effect and multidrug resistance of ovarian cancer through the PI3K signaling pathway. 2020. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20202683."},{"key":"2093_CR54","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.07.073","author":"Y Murakami","year":"2008","unstructured":"Murakami Y, Higashi Y, Matsunaga N, Koyanagi S, Ohdo S. Circadian clock-controlled intestinal expression of the multidrug-resistance gene mdr1a in mice. Gastroenterology. 2008. https:\/\/doi.org\/10.1053\/j.gastro.2008.07.073.","journal-title":"Gastroenterology"},{"issue":"6","key":"2093_CR55","doi-asserted-by":"publisher","first-page":"8945","DOI":"10.3892\/OL.2018.8488","volume":"15","author":"H Xu","year":"2018","unstructured":"Xu H, Wang Z, Mo G, Chen H. Association between circadian gene CLOCK and cisplatin resistance in ovarian cancer cells: a preliminary study. Oncol Lett. 2018;15(6):8945. https:\/\/doi.org\/10.3892\/OL.2018.8488.","journal-title":"Oncol Lett"},{"issue":"7","key":"2093_CR56","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/J.1349-7006.2006.00225.X","volume":"97","author":"H Hua","year":"2006","unstructured":"Hua H, et al. Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci. 2006;97(7):589\u201396. https:\/\/doi.org\/10.1111\/J.1349-7006.2006.00225.X.","journal-title":"Cancer Sci"},{"issue":"6","key":"2093_CR57","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3892\/OR.2013.2381","volume":"29","author":"CH Jung","year":"2013","unstructured":"Jung CH, et al. Bmal1 suppresses cancer cell invasion by blocking the phosphoinositide 3-kinase-Akt-MMP-2 signaling pathway. Oncol Rep. 2013;29(6):2109. https:\/\/doi.org\/10.3892\/OR.2013.2381.","journal-title":"Oncol Rep"},{"issue":"10","key":"2093_CR58","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1080\/00016340802348286","volume":"87","author":"H Tokunaga","year":"2008","unstructured":"Tokunaga H, et al. Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2008;87(10):1060\u201370. https:\/\/doi.org\/10.1080\/00016340802348286.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"1","key":"2093_CR59","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5732\/CJC.014.10289","volume":"34","author":"B Cheaib","year":"2015","unstructured":"Cheaib B, Auguste A, Leary A. The PI3K\/Akt\/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer. 2015;34(1):4. https:\/\/doi.org\/10.5732\/CJC.014.10289.","journal-title":"Chin J Cancer"},{"issue":"6","key":"2093_CR60","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.3892\/MMR.2016.5116","volume":"13","author":"Z Wang","year":"2016","unstructured":"Wang Z, Li L, Wang Y. Effects of Per2 overexpression on growth inhibition and metastasis, and on MTA1, nm23-H1 and the autophagy-associated PI3K\/PKB signaling pathway in nude mice xenograft models of ovarian cancer. Mol Med Rep. 2016;13(6):4561. https:\/\/doi.org\/10.3892\/MMR.2016.5116.","journal-title":"Mol Med Rep"}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-026-02093-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43032-026-02093-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-026-02093-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:09:50Z","timestamp":1783012190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43032-026-02093-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2093"],"URL":"https:\/\/doi.org\/10.1007\/s43032-026-02093-9","relation":{"references":[{"id-type":"doi","id":"10.1042\/BSR20202683","asserted-by":"subject"}]},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"value":"1933-7191","type":"print"},{"value":"1933-7205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}